Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ-I long-term outcomes study in adults with genotype 1 chronic hepatitis C
NL-OMON55830Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin in hepatitis C virus infection (2 arms), sponsored by AbbVie Inc. Primary endpoint: Effect of SVR12 on long-term clinical outcomes. Started Mar 2015; status: active, not recruiting.
02
Drugs
paritaprevirritonavirombitasvirdasabuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON55830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55830.